Quick Answer
ProMIS Neurosciences Inc. reported Net Income Loss of -$39.72 million for the year ending 2025.
- ProMIS Neurosciences Inc. showed a decrease of -1,529.3% in Net Income Loss from 2024 to 2025.
- This data is from ProMIS Neurosciences Inc.'s annual report (Form 10-K), filed with the SEC on March 25, 2026.
- XBRL data for this metric is available from 2021 to 2025 (5 years of filings). Earlier data may not exist in machine-readable XBRL format as companies adopted electronic filing at different times.
- Quarterly values from 10-Q filings: Q2 2021: -$225.5 thousand | Q3 2021: -$1.21 million | Q1 2022: -$2.09 million | Q2 2022: -$2.75 million | Q3 2022: -$5.96 million | Q1 2023: -$4.96 million | Q2 2023: -$2.31 million | Q3 2023: -$2.36 million | Q1 2024: -$3.64 million | Q2 2024: -$2.62 million | Q3 2024: $9.28 million | Q1 2025: -$7.35 million | Q2 2025: -$10.12 million | Q3 2025: -$11.58 million.
- Over the full 5 years of available data (2021 to 2025), ProMIS Neurosciences Inc.'s Net Income Loss has declined by 305.7%.
- Historical annual values: Fiscal year 2025: -$39.72 million | Fiscal year 2024: $2.78 million | Fiscal year 2023: -$13.21 million | Fiscal year 2022: -$18.06 million | Fiscal year 2021: -$9.79 million.
- Data sourced from SEC EDGAR public filings as of August 10, 2026.
Last verified: